Vitamin Shoppe Inc (NYSE:VSI) major shareholder Vintage Capital Management Llc bought 326,692 shares of Vitamin Shoppe stock in a transaction dated Friday, January 5th. The shares were bought at an average price of $4.96 per share, for a total transaction of $1,620,392.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Vintage Capital Management Llc also recently made the following trade(s):

  • On Tuesday, January 2nd, Vintage Capital Management Llc bought 133,804 shares of Vitamin Shoppe stock. The shares were bought at an average price of $4.28 per share, for a total transaction of $572,681.12.
  • On Saturday, December 29th, Vintage Capital Management Llc bought 234,343 shares of Vitamin Shoppe stock. The shares were bought at an average price of $4.36 per share, for a total transaction of $1,021,735.48.

Vitamin Shoppe Inc (NYSE VSI) opened at $5.00 on Thursday. Vitamin Shoppe Inc has a twelve month low of $2.95 and a twelve month high of $23.85. The firm has a market cap of $119.89, a P/E ratio of -0.47 and a beta of 0.68. The company has a quick ratio of 0.32, a current ratio of 2.07 and a debt-to-equity ratio of 0.59.

Vitamin Shoppe (NYSE:VSI) last announced its quarterly earnings data on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.17 by ($0.20). Vitamin Shoppe had a negative net margin of 20.27% and a positive return on equity of 6.17%. The business had revenue of $288.20 million during the quarter, compared to analyst estimates of $297.61 million. During the same quarter in the prior year, the company earned $0.50 earnings per share. The company’s quarterly revenue was down 8.5% on a year-over-year basis. equities analysts predict that Vitamin Shoppe Inc will post 0.34 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arizona State Retirement System increased its stake in Vitamin Shoppe by 0.8% in the second quarter. Arizona State Retirement System now owns 12,460 shares of the specialty retailer’s stock valued at $145,000 after purchasing an additional 100 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Vitamin Shoppe by 2.1% in the second quarter. BNP Paribas Arbitrage SA now owns 9,242 shares of the specialty retailer’s stock valued at $108,000 after purchasing an additional 192 shares in the last quarter. Martingale Asset Management L P increased its stake in Vitamin Shoppe by 4.7% in the second quarter. Martingale Asset Management L P now owns 27,008 shares of the specialty retailer’s stock valued at $315,000 after purchasing an additional 1,208 shares in the last quarter. Voya Investment Management LLC increased its stake in Vitamin Shoppe by 7.5% in the second quarter. Voya Investment Management LLC now owns 34,810 shares of the specialty retailer’s stock valued at $406,000 after purchasing an additional 2,414 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in Vitamin Shoppe by 9.3% in the second quarter. Legal & General Group Plc now owns 44,555 shares of the specialty retailer’s stock valued at $518,000 after purchasing an additional 3,789 shares in the last quarter. Institutional investors and hedge funds own 90.35% of the company’s stock.

VSI has been the topic of a number of research reports. ValuEngine upgraded shares of Vitamin Shoppe from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. Zacks Investment Research upgraded shares of Vitamin Shoppe from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Morgan Stanley reiterated an “equal weight” rating and set a $7.50 target price (down from $8.00) on shares of Vitamin Shoppe in a research report on Monday, October 2nd. Finally, Barclays reduced their target price on shares of Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 9th. Four investment analysts have rated the stock with a sell rating and five have given a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $5.00.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/11/vitamin-shoppe-inc-vsi-major-shareholder-buys-1620392-32-in-stock.html.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.